Skip to main content
Log In
Sign Up
Home
Watchlist
Stocks
Stock Screener
Stock Exchanges
Comparison Tool
Earnings Calendar
By Industry
Stock Lists
Top Analysts
Top Stocks
Corporate Actions
IPOs
Recent IPOs
IPO Calendar
IPO Statistics
IPO News
IPO Screener
ETFs
ETF Screener
Comparison Tool
New Launches
ETF Providers
News
Trending
Articles
Technical Chart
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After Hours
Market Heatmap
Market Newsletter
Stock Analysis Pro
Collapse
Neurocrine Biosciences, Inc. (FRA:NB3)
Germany
· Delayed Price · Currency is EUR
Full Chart
Watchlist
Compare
109.85
+1.85 (1.71%)
At close: Feb 20, 2026
Overview
Financials
Statistics
History
Profile
Chart
Income Statement
Balance Sheet
Cash Flow
Ratios
KPIs
Annual
Quarterly
TTM
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Download
Full Width
Fiscal Year
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2013
FY 2012
Period Ending
Dec '25
Dec 31, 2025
Dec '24
Dec 31, 2024
Dec '23
Dec 31, 2023
Dec '22
Dec 31, 2022
Dec '21
Dec 31, 2021
Dec '20
Dec 31, 2020
Dec '19
Dec 31, 2019
Dec '18
Dec 31, 2018
Dec '17
Dec 31, 2017
Dec '16
Dec 31, 2016
Dec '15
Dec 31, 2015
Dec '13
Dec 31, 2013
Dec '12
Dec 31, 2012
INGREZZA Revenue
2.51B
2.31B
INGREZZA Revenue Growth
8.65%
26.01%
CRENESSITY Revenue
301.20M
1.70M
CRENESSITY Revenue Growth
17617.65%
-
ONGENTYS and Other Product Revenue
19.00M
15.40M
ONGENTYS and Other Product Revenue Growth
23.38%
-37.40%
Total Net Product Revenue
2.83B
2.33B
Total Net Product Revenue Growth
21.59%
25.26%
Royalties Revenue
-
18.60M
Royalties Revenue Growth
-
-12.26%
Collaboration and Other Revenue
-
6.10M
Collaboration and Other Revenue Growth
-
15.09%
Total Collaboration Revenue
26.60M
24.70M
Total Collaboration Revenue Growth
7.69%
-6.79%
Revenue (Other)
-301.20M
-1.70M
Revenue (Total)
2.86B
2.36B
Revenue (Total) Growth
21.45%
24.81%
Updated Dec 31, 2025. Data Source:
Fiscal.ai
.